Current Trends in Targeted Therapies for Glioblastoma Multiforme

Figure 3

Combination with interferon-β: the JCOG0911 (INTEGRA) study. A randomized phase II clinical trial in patients with newly diagnosed GBM is under way to compare the standard-of-care regimen with the addition of IFN-β in the upfront settings.